Combining Aripiprazole with Paliperidone

Risks of Antipsychotic Polypharmacy

Antipsychotic polypharmacy has been associated with increased global side effect burden, including higher rates of Parkinsonian side effects, need for anticholinergic medications, hyperprolactinemia, sexual dysfunction, hypersalivation, sedation/somnolence, cognitive impairment, and diabetes mellitus 1
Drug-drug interactions may occur when combining antipsychotics that affect the same metabolic pathways, potentially leading to additive or reductive effects on plasma concentrations and increased severity of side effects 1
Guidelines consistently recommend antipsychotic monotherapy as the first-line approach, while some studies show that antipsychotic polypharmacy may be necessary for certain patients 1

If the current treatment is inadequate, consider optimizing the dose of a single antipsychotic before adding a second, and if switching medications is necessary, implement a gradual cross-titration rather than abrupt combination 4
For patients who truly require combination therapy, select antipsychotics with differing side-effect profiles 1
If combination therapy is absolutely necessary, start with lower doses of each medication to minimize side effects, regularly monitor for adverse effects, and have a clear treatment goal and timeline for reassessment 4

Studies show that approximately 20-33% of patients who switch from polypharmacy to monotherapy cannot tolerate the switch and require return to combination therapy 4
Patients with more severe symptoms or treatment resistance may sometimes benefit from carefully selected antipsychotic combinations, though this should be considered only after monotherapy options have been exhausted 4
The FDA has specifically warned against co-prescribing medications with similar mechanisms due to increased risk of adverse effects without clear evidence of additional benefit 5